Skip to main content
PepStack

DSIP

Nootropic & CNS
Delta Sleep-Inducing Peptide

Overview

Delta Sleep-Inducing Peptide (DSIP) is a neuropeptide that was first isolated from the cerebral venous blood of rabbits in 1977. It is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, and it is synthesized both naturally in the body and synthetically for research purposes. DSIP is primarily studied for its potential effects on sleep regulation, as its name suggests, but it has also been investigated for a variety of other physiological roles. Researchers have observed that DSIP may influence sleep patterns, particularly by promoting slow-wave sleep, and it has been studied for its potential to modulate stress responses, pain perception, and hormonal levels. Some studies suggest that DSIP may have anxiolytic and antidepressant effects, though these findings are preliminary and require further investigation. The mechanism of action of DSIP is not fully understood, but it is believed to interact with various neurotransmitter systems, including the modulation of GABAergic and glutamatergic pathways. It may also influence the release of corticotropin and other hormones, suggesting a complex role in neuroendocrine regulation. Pharmacokinetic studies indicate that DSIP has a relatively short half-life, with researchers reporting different values depending on the route of administration. It is considered to have poor oral bioavailability, which limits its effectiveness when taken orally. Current research on DSIP is ongoing, with studies exploring its potential therapeutic applications in sleep disorders, stress-related conditions, and other CNS-related issues. However, DSIP is not approved as a medicinal product by major regulatory agencies, and its use is primarily confined to research settings.

Mechanism of Action

DSIP is thought to interact with GABAergic and glutamatergic neurotransmitter systems, potentially influencing sleep regulation and stress response. It may also modulate the release of corticotropin and other hormones, indicating a role in neuroendocrine pathways.

Molecular Data

FormulaC35H48N10O15
Molecular Weight848.8 g/mol
CAS Number62568-57-4
PubChem CID68816

Half-Life

OralPoor bioavailability

DSIP's pharmacokinetic properties are not well-documented, and values may vary based on administration route.

Storage

Lyophilized

Stable for 2+ years at -20°C, 12 months at 4°C

Reconstituted

Use within 14 days when refrigerated at 4°C

Avoid

Avoid repeated freeze-thaw cycles, direct light

Solvent

Bacteriostatic water or sterile saline recommended

Solubility

DSIP is soluble in water and aqueous buffers, but data on solubility in organic solvents like acetonitrile or DMSO is limited.

Legal Status

🇩🇪DE

Not approved as a medicinal product. Not a controlled substance. Sale as research chemical is a legal grey area.

🇺🇸US

Not approved by the FDA as a medicinal product. Not scheduled by the DEA.

🇦🇺AU

Not listed on the TGA schedule.

🇬🇧UK

Not approved by the MHRA as a medicinal product.

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

8 Research Publications

Delta sleep-inducing peptide (DSIP): a still unresolved riddle.

Review

Journal of neurochemistry · 2006

Researchers reviewed the delta sleep-inducing peptide (DSIP), originally thought to promote sleep, but its role remains unclear due to insufficient evidence and lack of gene isolation. They propose the existence of similar peptides that may influence sleep-related activity, based on various studies highlighting their biological effects.

  • Researchers found that DSIP's connection to sleep is poorly documented and its biological activity remains largely unknown.
  • The study suggests the possibility of DSIP-like peptides that may have sleep-promoting effects, based on their specific distribution in the brain.
  • Certain artificial analogues of DSIP showed significant potential to promote slow-wave sleep in animal studies, unlike DSIP itself.
PubMed

Delta sleep-inducing peptide (DSIP)-like immunoreactivity in gut: coexistence with known peptide hormones.

Unknown

Peptides · 1989

Researchers found that a substance called delta sleep-inducing peptide-like immunoreactivity (DSIP-LI) is present in the gut of humans, pigs, and rats. The human gut had the highest concentration of this peptide, which coexists with other known gut hormones. This study highlights the potential role of DSIP-LI in gut function across different species.

  • DSIP-LI was found in various gut endocrine cells, particularly in humans.
  • The concentration of DSIP-LI was highest in human gut samples compared to those from pigs and rats.
  • A similar form of DSIP-like material was identified in all three species, suggesting a conserved presence.
PubMed

Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP).

Animal

European journal of pharmacology · 1988

Researchers studied the effects of a peptide called delta-sleep-inducing peptide (DSIP) on pain responses in mice and rats. They found that when administered into the brain, DSIP significantly reduced pain sensitivity, suggesting it may play a role in how the brain regulates pain.

  • DSIP produced a significant reduction in pain responses when given directly into the brain of mice and rats.
  • The pain-relieving effect of DSIP was blocked by an opioid antagonist, indicating its action may involve opioid receptors.
  • DSIP did not reduce pain in mice that were tolerant to morphine, suggesting its effects are distinct from those of traditional opioids.
PubMed

The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat.

Unknown

Brain research · 1987

Researchers investigated the effects of a synthetic peptide called delta-sleep-inducing peptide (DSIP) on sleep patterns in cats. They found that DSIP significantly increased deep sleep while reducing lighter sleep, suggesting that this peptide may enhance certain aspects of sleep quality.

  • DSIP administration led to a significant decrease in the time it took for cats to fall asleep.
  • There was a notable increase in deep slow wave sleep (S2) after DSIP injection, while light slow wave sleep (S1) decreased.
  • The increase in deep sleep was maintained for several hours but returned to baseline by the eighth hour.
PubMed

Delta sleep-inducing peptide (DSIP) stimulates LH release in steroid-primed ovariectomized rats.

Animal

Life sciences · 1987

Researchers studied the effects of delta sleep-inducing peptide (DSIP) on hormone release in female rats that had undergone ovariectomy. They found that DSIP stimulated the release of luteinizing hormone (LH) in rats that were primed with estrogen and progesterone, suggesting a link between DSIP and hormonal activity during sleep.

  • DSIP did not affect LH release in unprimed ovariectomized rats.
  • In estrogen and progesterone-primed rats, DSIP significantly stimulated LH release.
  • The study supports the idea that DSIP may activate brain circuits involved in hormone release during sleep.
PubMed

Delta-sleep-inducing peptide (DSIP): an update.

Review

Peptides · 1986

Researchers reviewed the delta-sleep-inducing peptide (DSIP), a substance studied since the 1960s for its effects on sleep and other bodily functions. They found that DSIP may support sleep and has potential therapeutic applications for conditions like insomnia and pain, while also suggesting links to certain diseases.

  • Researchers observed that DSIP has sleep-inducing effects in animals.
  • The study highlighted the potential therapeutic uses of DSIP for insomnia, pain, and withdrawal symptoms.
  • Researchers noted that DSIP's distribution in the body may relate to various diseases.
PubMed

Delta-sleep-inducing peptide (DSIP): a review.

Review

Neuroscience and biobehavioral reviews · 1984

Researchers reviewed the effects of a peptide called Delta-sleep-inducing peptide (DSIP), which has been shown to promote deep sleep in various animals, including humans. They found that DSIP influences not only sleep patterns but also brain activity, hormone levels, and psychological performance.

  • DSIP is a peptide that induces mainly delta-sleep in multiple species, including humans.
  • The peptide affects brain activity and neurotransmitter levels, influencing overall sleep quality.
  • DSIP also impacts circadian rhythms, hormonal levels, and psychological performance.
PubMed

Delta sleep-inducing peptide (DSIP)-like material is absorbed by the gastrointestinal tract of the neonatal rat.

Unknown

Life sciences · 1983

Researchers studied how a specific peptide, known as delta sleep-inducing peptide (DSIP), is absorbed through the gastrointestinal tract in neonatal rats. They found that when the rats were fed a version of this peptide, it entered their bloodstream and even reached their brains, indicating that it can cross the blood-brain barrier.

  • Researchers found that feeding neonatal rats a peptide analog led to significant increases in DSIP-like substances in their blood.
  • The study observed that the peptide could cross into the brain, suggesting it effectively penetrates the blood-brain barrier.
  • Additionally, there was a small increase in plasma DSIP-like substances when nursing mothers were injected with the peptide.
PubMed

Track DSIP in PepStack

Log your research cycles, set reminders and visualize serum levels.

Download on theApp StoreGet it onGoogle Play

This page is for informational and research purposes only. All information is based on published scientific literature. Nothing on this page constitutes medical advice or replaces consultation with a qualified healthcare professional.